Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1657359 | 0.93 | FDPS (0.34) | SPHK1FDPS | |
| SCHEMBL8896811 | 0.91 | GGPS1 (0.38) | SPHK1FDPSMAPT | |
| SCHEMBL1659023 | 0.85 | TSHR (0.38) | TSHRCYP1A2CYP3A4CYP2C9HIF1A | |
| SCHEMBL20609969 | 0.80 | LMNA (0.30) | TSHR | |
| SCHEMBL8895383 | 0.79 | TSHR (0.33) | TSHRFDPSMAPK1 | |
| SCHEMBL8368013 | 0.79 | TSHR (0.33) | TSHRCYP1A2CYP3A4CYP2C9HIF1A | |
| SCHEMBL1658197 | 0.79 | FDPS (0.34) | TSHRSPHK1FDPSMAPK1 | |
| SCHEMBL21925461 | 0.76 | — | — | |
| SCHEMBL11422347 | 0.76 | TSHR (0.35) | TSHRSPHK1FDPSMAPT | |
| SCHEMBL22117524 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8632792-B2 | Cooling sensation agent composition and sensory stimulation agent composition | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20130131169-A1 | COOLING SENSATION AGENT COMPOSITION, SENSORY STIMULATION AGENT COMPOSITION AND USE OF THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-05-23 | — | — | US | disclosed |
| US-8377458-B2 | Cooling sensation agent composition, sensory stimulation agent composition and use of the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20110117147-A1 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110081393-A1 | COOLING SENSATION AGENT COMPOSITION, SENSORY STIMULATION AGENT COMPOSITION AND USE OF THE SAME | TAKASAGO INTERNATIONAL CORPORATION | 2011-04-07 | — | — | US | disclosed |
| WO-2009123355-A2 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117147-A1 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TRPA1, HRH1, HRH2 | TSHR 2479/4885CYP1A2 856/4885CYP3A4 2262/4885 |
| US-20110081393-A1 | COOLING SENSATION AGENT COMPOSITION, SENSORY STIMULATION AGENT COMPOSITION AND USE OF THE SAME | TRPA1, TRPV1, TRPM4 | TSHR 3786/4885CYP1A2 2078/4885CYP3A4 2269/4885 |
| US-20130131169-A1 | COOLING SENSATION AGENT COMPOSITION, SENSORY STIMULATION AGENT COMPOSITION AND USE OF THE SAME | TRPA1, TRPV1, TRPM4 | TSHR 3786/4885CYP1A2 2078/4885CYP3A4 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.